SELECT TAVR Trial to Compare Myval and Evolut Valves in Borderline Annuli Patients
The SELECT TAVR trial will assess the noninferiority of Myval transcatheter heart valves compared to Evolut valves in patients with borderline annular dimensions.
Focal Asset
Myval
Indication
Cardiology / Transcatheter Aortic Valve Replacement
Signal Score
8.2
Signal assessment
Signal strength
high
Confidence level
moderate
Why it matters
The SELECT TAVR trial's outcomes could significantly impact the competitive landscape for transcatheter heart valves, particularly between Myval and Evolut. If Myval demonstrates non-inferiority or superiority, it may shift clinical practices and market share in TAVI procedures, especially for patients with complex anatomical profiles.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor trial results for safety and hemodynamic performance metrics at 30 days and longer-term follow-up outcomes.
Related companies & assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.